

August 3, 2021

To,
**SINGAPORE EXCHANGE SECURITIES
TRADING LIMITED**
11 North Buona Vista Drive,
#06-07 The Metropolis Tower 2,
Singapore – 138589

Dear Sirs/Madam,

Sub: Initial public offering ("Offer") of equity shares of our wholly owned subsidiary "Glenmark Life Sciences Limited"

This is further to our intimations dated April 16, 2021 and July 20, 2021 regarding the submission of the draft red herring prospectus dated April 16, 2021 ("DRHP"), with the Securities and Exchange Board of India and filing of the red herring prospectus dated July 19, 2021 with the Registrar of Companies, Pune at Maharashtra ("ROC") by our wholly owned subsidiary, Glenmark Life Sciences Limited. We would like to inform you of the following:

- a. The IPO comprised of a fresh issue of 14,722,222 equity shares by Glenmark Life Sciences Limited and an offer for sale of 6,300,000 equity shares by the Company. The IPO opened for subscription on July 27, 2021 and closed on July 29, 2021.
- b. Glenmark Life Sciences Limited filed the prospectus with the ROC on July 30, 2021.
- c. The equity shares of the Glenmark Life Sciences Limited, pursuant to the IPO, were allotted at an offer price of Rs. 720 per equity share, to the successful bidders on August 3, 2021.
- d. Post the above allotment, the shareholding percentage of the Company in Glenmark Life Sciences Limited has reduced from 100% to 82.84%.

We request you to kindly take the above information on record.

Thanking you,

Yours faithfully,

For Glenmark Pharmaceuticals Limited



Harish Kuber
Company Secretary and Compliance Officer

Tel: 4018 9999 / 4018 9879

Fax: 4018 9986 (Legal & Secretarial Dept.)

Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com